• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于有限吸收时间概念视角下的生理药代动力学模型

Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept.

作者信息

Wu Di, Tsekouras Athanasios A, Macheras Panos, Kesisoglou Filippos

机构信息

Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Department of Chemistry, Laboratory of Physical Chemistry, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Pharm Res. 2023 Feb;40(2):419-429. doi: 10.1007/s11095-022-03357-0. Epub 2022 Sep 1.

DOI:10.1007/s11095-022-03357-0
PMID:36050545
Abstract

To date, mechanistic modeling of oral drug absorption has been achieved via the use of physiologically based pharmacokinetic (PBPK) modeling, and more specifically, physiologically based biopharmaceutics model (PBBM). The concept of finite absorption time (FAT) has been developed recently and the application of the relevant physiologically based finite time pharmacokinetic (PBFTPK) models to experimental data provides explicit evidence that drug absorption terminates at a specific time point. In this manuscript, we explored how PBBM and PBFTPK models compare when applied to the same dataset. A set of six compounds with clinical data from immediate-release formulation were selected. Both models resulted in absorption time estimates within the small intestinal transit time, with PBFTPK models generally providing shorter time estimates. A clear relationship between the absorption rate and the product of permeability and luminal concentration was observed, in concurrence with the fundamental assumptions of PBFTPK models. We propose that future research on the synergy between the two modeling approaches can lead to both improvements in the initial parameterization of PBPK/PBBM models but to also expand mechanistic oral absorption concepts to more traditional pharmacometrics applications.

摘要

迄今为止,口服药物吸收的机制建模是通过使用基于生理学的药代动力学(PBPK)建模,更具体地说是基于生理学的生物药剂学模型(PBBM)来实现的。有限吸收时间(FAT)的概念最近已被提出,相关的基于生理学的有限时间药代动力学(PBFTPK)模型在实验数据中的应用提供了明确的证据,表明药物吸收在特定时间点终止。在本手稿中,我们探讨了将PBBM和PBFTPK模型应用于同一数据集时的比较情况。选择了一组有速释制剂临床数据的六种化合物。两种模型得出的吸收时间估计值均在小肠转运时间范围内,PBFTPK模型通常提供更短的时间估计值。观察到吸收速率与渗透率和管腔浓度乘积之间存在明确关系,这与PBFTPK模型的基本假设一致。我们建议,未来对这两种建模方法协同作用的研究不仅可以改进PBPK/PBBM模型的初始参数化,还可以将机制性口服吸收概念扩展到更传统的药物计量学应用中。

相似文献

1
Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept.基于有限吸收时间概念视角下的生理药代动力学模型
Pharm Res. 2023 Feb;40(2):419-429. doi: 10.1007/s11095-022-03357-0. Epub 2022 Sep 1.
2
Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of Clinical Studies: Current Status, Challenges, and Opportunities.基于生理学的药代动力学/药效动力学模型在支持临床研究豁免中的应用:现状、挑战和机遇。
Mol Pharm. 2021 Jan 4;18(1):1-17. doi: 10.1021/acs.molpharmaceut.0c00903. Epub 2020 Dec 15.
3
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.基于模型的生物药剂学实验分析,以改善机制口服吸收建模:以酮康唑为模型药物的体外-体内外推综合视角。
Mol Pharm. 2017 Dec 4;14(12):4305-4320. doi: 10.1021/acs.molpharmaceut.7b00406. Epub 2017 Aug 25.
4
Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.考虑延长释放药物产品生理基于生物药剂学模型中结肠吸收的方法。
Mol Pharm. 2023 Dec 4;20(12):6272-6288. doi: 10.1021/acs.molpharmaceut.3c00683. Epub 2023 Oct 30.
5
Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.基于生理的人体区域性和结肠吸收的生物药剂学模型。
Eur J Pharm Biopharm. 2023 May;186:144-159. doi: 10.1016/j.ejpb.2023.03.013. Epub 2023 Apr 5.
6
Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.犬类局部及结肠吸收的基于生理学的生物药剂学建模
Mol Pharm. 2021 Apr 5;18(4):1699-1710. doi: 10.1021/acs.molpharmaceut.0c01201. Epub 2021 Mar 15.
7
PBPK models for the prediction of in vivo performance of oral dosage forms.用于预测口服剂型体内性能的生理药代动力学(PBPK)模型。
Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21.
8
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.在药物开发和监管应用的 PBPK 建模中纳入溶出数据的现状和未来机遇:OrBiTo 联盟评论。
Eur J Pharm Biopharm. 2020 Oct;155:55-68. doi: 10.1016/j.ejpb.2020.08.005. Epub 2020 Aug 8.
9
Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products.生理基础吸收和药代动力学建模在口服改剂型仿制药开发过程中的应用。
Eur J Pharm Biopharm. 2022 Jul;176:87-94. doi: 10.1016/j.ejpb.2022.05.007. Epub 2022 May 19.
10
Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.基于生理的药代动力学模型的食物效应预测:预测性案例研究。
J Pharm Sci. 2019 Jan;108(1):592-602. doi: 10.1016/j.xphs.2018.05.024. Epub 2018 Jun 12.

引用本文的文献

1
Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence.有限吸收时间(F.A.T.)概念在生物等效性评估中的应用。
Pharm Res. 2024 Jul;41(7):1413-1425. doi: 10.1007/s11095-024-03727-w. Epub 2024 Jun 19.
2
Importance of Considering Fed-State Gastrointestinal Physiology in Predicting the Reabsorption of Enterohepatic Circulation of Drugs.考虑 fed-state 胃肠道生理学在预测药物肠肝循环重吸收中的重要性。
Pharm Res. 2024 Apr;41(4):673-685. doi: 10.1007/s11095-024-03669-3. Epub 2024 Mar 12.
3
IVIVC Revised.

本文引用的文献

1
Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models.重写基于生理的有限时间药代动力学(PBFTPK)模型的口服药代动力学。
Pharm Res. 2022 Apr;39(4):691-701. doi: 10.1007/s11095-022-03230-0. Epub 2022 Apr 4.
2
Lost in modelling and simulation?迷失在建模与仿真中?
ADMET DMPK. 2021 Mar 22;9(2):75-109. doi: 10.5599/admet.923. eCollection 2021.
3
Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts.半个世纪后重新审视地高辛的生物利用度:生物利用度概念变革之时。
IVIVC 修订版。
Pharm Res. 2024 Feb;41(2):235-246. doi: 10.1007/s11095-024-03653-x. Epub 2024 Jan 8.
4
Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption.重新构建具有科学和监管意义的生物药剂学-药代动力学,以改善口服药物吸收。
Pharm Res. 2023 Sep;40(9):2167-2175. doi: 10.1007/s11095-023-03578-x. Epub 2023 Aug 3.
5
Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept.重新审视鼻内和肌肉注射后纳洛酮药代动力学使用有限吸收时间概念。
Eur J Drug Metab Pharmacokinet. 2023 Jul;48(4):455-462. doi: 10.1007/s13318-023-00831-x. Epub 2023 Jun 2.
Pharm Res. 2021 Oct;38(10):1635-1638. doi: 10.1007/s11095-021-03121-w. Epub 2021 Oct 18.
4
Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.利用生理相关药代动力学建模(PBBM)确定即释口服剂型的生物等效性安全范围:案例研究。
J Pharm Sci. 2021 Dec;110(12):3896-3906. doi: 10.1016/j.xphs.2021.09.017. Epub 2021 Sep 20.
5
Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.修订口服药物吸收的药代动力学:二、生物利用度-生物等效性的考虑。
Pharm Res. 2021 Aug;38(8):1345-1356. doi: 10.1007/s11095-021-03078-w. Epub 2021 Aug 2.
6
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network.当前口服吸收研究的挑战和未来展望:UNGAP 网络的观点。
Adv Drug Deliv Rev. 2021 Apr;171:289-331. doi: 10.1016/j.addr.2021.02.001. Epub 2021 Feb 18.
7
Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.生理相关生物药剂学建模的开发与验证最佳实践。研讨会总结报告
J Pharm Sci. 2021 Feb;110(2):584-593. doi: 10.1016/j.xphs.2020.09.058. Epub 2020 Oct 13.
8
In Vitro Biopredictive Methods: A Workshop Summary Report.体外生物预测方法:研讨会总结报告。
J Pharm Sci. 2021 Feb;110(2):567-583. doi: 10.1016/j.xphs.2020.09.021. Epub 2020 Sep 19.
9
Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts.修订口服药物吸收的药代动力学:I 基于生物制药/生理和有限吸收时间概念的模型。
Pharm Res. 2020 Sep 4;37(10):187. doi: 10.1007/s11095-020-02894-w.
10
The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.生物药剂学分类系统(BCS)和生物药剂学药物处置分类系统(BDDCS):超越指南。
Int J Pharm. 2019 Jul 20;566:264-281. doi: 10.1016/j.ijpharm.2019.05.041. Epub 2019 May 17.